Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 39

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Oct 21, 2013; 19(39): 6515-6522
Published online Oct 21, 2013. doi: 10.3748/wjg.v19.i39.6515

Table 2 Components of the risk scores

Factor	Risk score
Factor	CU-HCC	GAG-HCC (yr)	REACH-B
Age (yr)	≤ 50: 0		30-34: 0
	>50: 3		35-39: 1
			40-44: 2
			45-49: 3
			50-54: 4
			55-59: 5
			60-65: 6
Sex	NA	Male: 16	Male: 2
Sex	NA	Female: 0	Female: 0
Albumin (g/L)	≤ 35: 20	NA	NA
Albumin (g/L)	> 35: 0	NA	NA
Bilirubin (mmol/L)	≤ 18: 0	NA	NA
Bilirubin (mmol/L)	> 18: 1.5	NA	NA
ALT (U/L)	NA	NA	< 15: 0
			15-44: 1
			≥ 45: 2
HBeAg	NA	NA	Positive: 2
HBeAg	NA	NA	Negative: 0
HBV DNA (copies/mL)	< 4 log: 0	3 × in log	< 4 log: 0
	4-6 log: 1		4-5 log: 3
	> 6 log: 4		5-6 log: 5
	(lack of maintained virologic suppression: 4)		≥ 6 log: 4 (lack of maintained virologic suppression: 4)
Cirrhosis	Presence: 15	Presence: 33	NA
Cirrhosis	Absence: 0	Absence: 0	NA

ALT: Alanine aminotransferase; HBeAg: Hepatitis B e antigen; NA: Not applicable; HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus.

Citation: Wong GLH, Wong VWS. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. World J Gastroenterol 2013; 19(39): 6515-6522
URL: https://www.wjgnet.com/1007-9327/full/v19/i39/6515.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i39.6515

Wong GLH, Wong VWS. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. World J Gastroenterol 2013; 19(39): 6515-6522 [PMID: 24151375 DOI: 10.3748/wjg.v19.i39.6515]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.